Home Cart Sign in  
Chemical Structure| 35807-85-3 Chemical Structure| 35807-85-3

Structure of Tauroursodeoxycholate sodium
CAS No.: 35807-85-3

Chemical Structure| 35807-85-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium is an endoplasmic reticulum (ER) stress inhibitor that significantly reduces the expression of apoptosis molecules such as caspase-3 and caspase-12 and also inhibits ERK.

Synonyms: Tauroursodeoxycholic acid sodium; UR 906 sodium; Ursodeoxycholyltaurine sodium

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Zhang, Junlin ; Wu, Yucheng ; Zhang, Jie ; Zhang, Rui ; Wang, Yiting ; Liu, Fang

Abstract: Background: Hyperglycemia and dyslipidemia are two major characteristics of diabetes. In this study, the effects of glomerular cholesterol accumulation primarily due to ABCA1 deficiency on glomerular endothelial injury in diabetic kidney disease (DKD) and the possible mechanisms were investigated. Methods: The effects of ABCA1 deficiency on glomerular lipid deposition and kidney injury were examined in a type 2 diabetic mouse model with ABCA1 deficiency in glomerular endothelial cells (DM-ABCA1− /− mice) and human renal glomerular endothelial cells (HRGECs) cultured in high glucose and high cholesterol conditions, which simulated type 2 diabetes in vitro. Results: ABCA1 deficiency in glomerular endothelial cells exacerbated renal lipid deposition and kidney injuries in type 2 diabetic mice and manifested as increased creatinine levels, more severe proteinuria, mesangial matrix expansion and fusion of foot processes, and more pronounced renal inflammatory injury and cell death. In HRGECs cultured under high glucose and high cholesterol conditions, ABCA1 deficiency increased the deposition of cellular cholesterol, contributed to inflammation and apoptosis, damaged the endothelial glycocalyx barrier, and induced endoplasmic reticulum stress (ERS). Conversely, ABCA1 overexpression enhancing cholesterol efflux or inhibition of ERS in vitro, significantly protected against glomerular endothelial injury stimulated by high glucose and high cholesterol. Conclusions: These findings establish a pathogenic role of ABCA1 deficiency in glomerular endothelium injury and dysfunction and imply that ABCA1 may represent a potential effective therapeutic target for early diabetic kidney disease.

Keywords: ABCA1 ; Glomerular endothelial cell ; Diabetic kidney disease ; Cholesterol efflux ; Endoplasmic reticulum stress

Purchased from AmBeed: ;

Alternative Products

Product Details of Tauroursodeoxycholate sodium

CAS No. :35807-85-3
Formula : C26H45NNaO6S
M.W : 522.69
SMILES Code : C[C@@]12[C@]([C@]3([C@@]([C@]4(C)[C@](C[C@@H]3O)(C[C@H](O)CC4)[H])(CC1)[H])[H])(CC[C@@]2([C@@H](CCC(NCCS(=O)(=O)O)=O)C)[H])[H].[Na]
Synonyms :
Tauroursodeoxycholic acid sodium; UR 906 sodium; Ursodeoxycholyltaurine sodium
MDL No. :MFCD00065451

Safety of Tauroursodeoxycholate sodium

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Tauroursodeoxycholate sodium

MAPK

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03127514 Amyotrophic Lateral Sclerosis ... More >> Motor Neuron Disease Neuromuscular Diseases Neurodegenerative Diseases Spinal Cord Diseases TDP-43 Proteinopathies Nervous System Diseases Central Nervous System Diseases Less << Phase 2 Recruiting May 2019 -
NCT00771901 - Completed - -
NCT03533257 Alzheimer Disease Phase 2 Recruiting September 1, 2020 United States, Illinois ... More >> Rush University Medical Center Recruiting Chicago, Illinois, United States, 60612 Contact: Judy Phillips    312-942-0050    Judy_Phillips@rush.edu    United States, Kansas University of Kansas Clinical Research Center Recruiting Fairway, Kansas, United States, 66205 Contact: KUMC Recruitment Division    913-588-0555    KUAMP@kumc.edu    United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Alison J McManus, DNP    617-643-4848    ajmcmanus@mgh.harvard.edu    Contact: John Ernandez    617-643-4047    jernandez@partners.org    United States, New Jersey Rowan University Not yet recruiting Stratford, New Jersey, United States, 08084 Contact: Lauren Fedor    856-566-6003    fedor@rowan.edu    United States, New York Mount Sinai Alzheimer's Disease Research Center Not yet recruiting New York, New York, United States, 10029 Contact: Caroline Meuser    212-659-8885    caroline.meuser@mssm.edu    Columbia University Recruiting New York, New York, United States, 10032 Contact: Ruth Tejeda    212-305-7661    rbt41@cumc.columbia.edu    United States, Pennsylvania Penn Memory Center Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Laura Schankel    215-349-8727    laura.schankel@pennmedicine.upenn.edu Less <<
NCT00771901 Insulin Resistance ... More >> Diabetes Obesity Less << Not Applicable Completed - United States, Missouri ... More >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.91mL

0.38mL

0.19mL

9.57mL

1.91mL

0.96mL

19.13mL

3.83mL

1.91mL

References

 

Historical Records

Categories